Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2MlMg4Q
via IFTTT